Kanwal Raghav on trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02)

Update: 2024-08-27

Description

Dr Kanwal Raghav (Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA) discusses his Article entitled, ‘Trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a randomised, multicentre, phase 2 trial’.

Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00380-2/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

Tell us what you thought about this episode

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Comments

Top Podcasts

The Best New Comedy Podcast Right Now – June 2024 The Best News Podcast Right Now – June 2024 The Best New Business Podcast Right Now – June 2024 The Best New Sports Podcast Right Now – June 2024 The Best New True Crime Podcast Right Now – June 2024 The Best New Joe Rogan Experience Podcast Right Now – June 20 The Best New Dan Bongino Show Podcast Right Now – June 20 The Best New Mark Levin Podcast – June 2024

In Channel

Yannick Romero on the changing landscape of national cancer control plans

2025-01-0224:40

M Saiful Huq and Mostafa Aziz Sumon on the series Cancer Care in South Asian Association for Regional Cooperation (SAARC) Countries

2024-12-0222:15

$Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma$

Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma

2024-10-3015:07

Zachary Zumsteg on early phase trial design for novel drug-radiotherapy combination

2024-09-3017:21

May Abdel-Wahab and Andrew Scott on The Lancet Oncology Commission on Radiotherapy and Theranostics

2024-09-3040:45

Kanwal Raghav on trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02)

2024-08-2713:22

Emmy Boerrigter on dose selection of novel anticancer drugs

2024-07-2911:41

Hisham Mehanna and Sue Yom on head and neck cancer consensus recommendations

2024-06-2436:56

Garth Strohbehn and Katie Lichter on the environmental impact of cancer treatment

2024-05-2824:08

James Shultz, Ana Patricia Ortiz, and Leticia Nogueira on cancer and compounding disasters in the Caribbean

2024-04-2935:05

Bernardo Goulart on correlations of endpoints in lung cancer immunotherapy trials

2024-04-0811:22

Maria Kyrgiou on innovations in gynaecological cancers and global disparities

2024-03-0725:42

Georgios Lyratzopoulos on the use of chemotherapy and radiotherapy in patients with eight common cancers

2024-02-2634:43

Mike Sathekge on radioligand therapy of metastatic castration-resistant prostate cancer

2024-01-2916:06

Shankar Siva on stereotactic body radiotherapy for primary renal cell carcinoma

2024-01-0213:53

Neerja Bhatla on a new quadrivalent HPV vaccine

2023-11-2912:24

Chandra Are on the Lancet Oncology Commission on Global Cancer Surgery

2023-11-0143:49

Philipp Karschnia on tissue sampling and processing during resection of diffuse intracranial glioma

2023-10-3117:10

Wanda Cui on measuring ovarian toxicity

2023-10-0310:37

Ticiana Leal on Tumour Treating Fields

2023-09-0109:01

00:00

1.0x

Kanwal Raghav on trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02)

#box-pro-ellipsis-173692816114943{-webkit-line-clamp:2;}Kanwal Raghav on trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02)

Kanwal Raghav on trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02)

The Lancet Group

Kanwal Raghav on trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02)